FDA meeting rescheduled
This article was originally published in The Tan Sheet
Executive Summary
Manufacturing Subcommittee of the Advisory Committee on Pharmaceutical Science, which was slated to meet March 21, will instead combine that agenda with next scheduled meeting May 21-22. Inaugural meeting of the subcommittee was cancelled due to war in Iraq; FDA was expected to outline its progress on the "Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach" initiative (1"The Tan Sheet" Sept. 2, 2002, p. 13)...
You may also be interested in...
Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.